[go: up one dir, main page]

RU2001123035A - CHEMICAL COMPOUNDS - Google Patents

CHEMICAL COMPOUNDS

Info

Publication number
RU2001123035A
RU2001123035A RU2001123035/14A RU2001123035A RU2001123035A RU 2001123035 A RU2001123035 A RU 2001123035A RU 2001123035/14 A RU2001123035/14 A RU 2001123035/14A RU 2001123035 A RU2001123035 A RU 2001123035A RU 2001123035 A RU2001123035 A RU 2001123035A
Authority
RU
Russia
Prior art keywords
glucopyranose
benzylidene
pharmaceutically acceptable
viruses
benzaldehyde derivative
Prior art date
Application number
RU2001123035/14A
Other languages
Russian (ru)
Inventor
Бернт БЁРРЕТСЕН (NO)
Бернт БЁРРЕТСЕН
Видар МОЭН (NO)
Видар МОЭН
Рольф Олаф ЛАРСЕН (NO)
Рольф Олаф ЛАРСЕН
Эрик Олай ПЕТТЕРСЕН (NO)
Эрик Олай ПЕТТЕРСЕН
Камилла Бруно ДУНСЕД (NO)
Камилла Бруно ДУНСЕД
Гейр САГВОЛЬДЕН (NO)
Гейр САГВОЛЬДЕН
Original Assignee
Норск Хюдро АСА (NO)
Норск Хюдро Аса
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Норск Хюдро АСА (NO), Норск Хюдро Аса filed Critical Норск Хюдро АСА (NO)
Publication of RU2001123035A publication Critical patent/RU2001123035A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (6)

1. Применение 4,6-О-(бензилиден-d1)-D-глюкопиранозы, 4,6-O-бензилиден-L-глюкопиранозы и/или 4,6-О-(бензилиден-d1)-L-глюкопиранозы либо их фармацевтически приемлемой соли для производства фармацевтического препарата для профилактики и/или лечения рака печени, рака почек и рака поджелудочной железы.1. Use of 4,6-O- (benzylidene-d 1 ) -D-glucopyranose, 4,6-O-benzylidene-L-glucopyranose and / or 4,6-O- (benzylidene-d 1 ) -L-glucopyranose or a pharmaceutically acceptable salt thereof, for the manufacture of a pharmaceutical preparation for the prophylaxis and / or treatment of liver cancer, kidney cancer, and pancreatic cancer. 2. Применение по п.1 для производства фармацевтического препарата для профилактического лечения раков, индуцируемых вирусами, такими как вирусы гепатита В и С, онкогенные вирусы папилломы и другие онкогенные вирусы.2. The use according to claim 1 for the manufacture of a pharmaceutical preparation for the prophylactic treatment of cancers induced by viruses, such as hepatitis B and C viruses, oncogenic papilloma viruses and other oncogenic viruses. 3. Бензальдегидное производное, полезное в качестве терапевтического агента, представляющее собой 4,6-O-бензилиден-L-глюкопиранозу и/или 4,6-O-(бензилиден-d1)-L-глюкопиранозу либо их фармацевтически приемлемую соль.3. A benzaldehyde derivative useful as a therapeutic agent, which is 4,6-O-benzylidene-L-glucopyranose and / or 4,6-O- (benzylidene-d 1 ) -L-glucopyranose or a pharmaceutically acceptable salt thereof. 4. Фармацевтическая композиция, содержащая бензальдегидное производное по любому из пп.1-3 и фармацевтически приемлемый носитель, разбавитель и/или эксципиент.4. A pharmaceutical composition comprising a benzaldehyde derivative according to any one of claims 1 to 3 and a pharmaceutically acceptable carrier, diluent and / or excipient. 5. Способ производства фармацевтической композиции, при котором осуществляют стадию объединения бензальдегидного производного, как оно определено в любом из пп.1-4, с фармацевтически приемлемым носителем, разбавителем и/или эксципиентом.5. A method of manufacturing a pharmaceutical composition in which the step of combining a benzaldehyde derivative, as defined in any one of claims 1 to 4, is carried out with a pharmaceutically acceptable carrier, diluent and / or excipient. 6. Бензальдегидное производное, представляющее собой 4,6-O-бензилиден-L-глюкопиранозу, 4,6-O-(бензилиден-d2)-L-глюкопиранозу либо их фармацевтически приемлемую соль.6. The benzaldehyde derivative, which is 4,6-O-benzylidene-L-glucopyranose, 4,6-O- (benzylidene-d 2 ) -L-glucopyranose or a pharmaceutically acceptable salt thereof.
RU2001123035/14A 1999-02-19 2000-02-18 CHEMICAL COMPOUNDS RU2001123035A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO990814A NO309305B1 (en) 1999-02-19 1999-02-19 Use of benzaldehyde derivatives in the manufacture of pharmaceutical preparations for the prevention and / or treatment of cancer, as well as certain new benzaldehyde derivatives
NO19990814 1999-02-19

Publications (1)

Publication Number Publication Date
RU2001123035A true RU2001123035A (en) 2004-03-20

Family

ID=19902986

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2001123035/14A RU2001123035A (en) 1999-02-19 2000-02-18 CHEMICAL COMPOUNDS
RU2001123124/15A RU2001123124A (en) 1999-02-19 2000-02-18 Chemical compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2001123124/15A RU2001123124A (en) 1999-02-19 2000-02-18 Chemical compounds

Country Status (15)

Country Link
EP (2) EP1150690A1 (en)
JP (2) JP2002537263A (en)
CN (2) CN1347323A (en)
AU (2) AU2834100A (en)
BR (2) BR0008302A (en)
CA (2) CA2363670A1 (en)
CZ (2) CZ20012966A3 (en)
HU (2) HUP0105280A2 (en)
IL (2) IL144895A0 (en)
MX (2) MXPA01008346A (en)
NO (1) NO309305B1 (en)
PL (2) PL350520A1 (en)
RU (2) RU2001123035A (en)
SK (2) SK11602001A3 (en)
WO (2) WO2000048610A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4182218B2 (en) * 2001-05-30 2008-11-19 学校法人東京理科大学 Novel glucose derivative that induces apoptosis, process for its production and its use as a medicament
DE10261807A1 (en) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterated catecholamine derivatives and medicinal products containing these compounds
NZ565078A (en) * 2005-07-26 2010-03-26 Nycomed Gmbh Deuterated proton pump inhibitors such as omeprazole
EP1912947A1 (en) * 2005-07-26 2008-04-23 Nycomed GmbH Isotopically substituted pantoprazole
JP2009511481A (en) * 2005-10-06 2009-03-19 オースペックス・ファーマシューティカルズ・インコーポレイテッド Gastric H +, K + -ATPase deuteration inhibitors with enhanced therapeutic properties
CN101157711B (en) * 2007-09-28 2010-12-08 西安交通大学 A compound with antitumor activity and its use
JP2011516478A (en) * 2008-04-03 2011-05-26 コグネイト ３，エルエルシー Compositions and methods for immunotherapy
CN101735284B (en) * 2008-11-24 2012-05-23 上海医药工业研究院 Preparation method of 4, 6-O-benzylidene-D-glucopyranose
PL3076967T3 (en) 2013-12-03 2021-12-20 Intra-Cellular Therapies, Inc. METHODS OF TREATMENT OF RESIDUAL SYMPTOMS OF SCHIZOPHRENIA
MX388258B (en) 2014-04-04 2025-03-19 Intra Cellular Therapies Inc Organic compounds
JP6898072B2 (en) * 2015-08-27 2021-07-07 秀行 佐谷 14-3-3 Protein activity regulator
PL3407889T3 (en) 2016-03-25 2021-11-22 Intra-Cellular Therapies, Inc. Organic compounds and their use in treating or preventing central nervous system disorders
US11331316B2 (en) 2016-10-12 2022-05-17 Intra-Cellular Therapies, Inc. Amorphous solid dispersions
KR20240141212A (en) 2017-03-24 2024-09-25 인트라-셀룰라 써래피스, 인코퍼레이티드. Novel compositions and methods
EP3843729A4 (en) 2018-08-29 2022-06-01 Intra-Cellular Therapies, Inc. Novel compositions and methods
CN118873536A (en) 2018-08-31 2024-11-01 细胞内治疗公司 New approach
WO2020047407A1 (en) 2018-08-31 2020-03-05 Intra-Cellular Therapies, Inc. Novel methods
EP4134101A1 (en) 2019-07-07 2023-02-15 Intra-Cellular Therapies, Inc. Deuterated lumateperone for the treatment of the bipolar ii disorder
US12414948B2 (en) 2022-05-18 2025-09-16 Intra-Cellular Therapies, Inc. Methods

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB811510A (en) * 1954-12-20 1959-04-08 Gyogyszeripari Ki New nitrogen-containing derivatives of polyhydroxy compounds and process for the preparation thereof
JPS6112623A (en) * 1984-06-28 1986-01-21 Kaken Pharmaceut Co Ltd enkephalinase inhibitor
JPS6256423A (en) * 1985-09-06 1987-03-12 Kaken Pharmaceut Co Ltd Remedy and ameliorating agent for cachexia
GB8705780D0 (en) * 1987-03-11 1987-04-15 Norsk Hydro As Anticancer compounds
JPH07145191A (en) * 1993-11-24 1995-06-06 Japan Tobacco Inc Galactosyl phosphonate derivative

Also Published As

Publication number Publication date
BR0008297A (en) 2002-05-28
WO2000048610A1 (en) 2000-08-24
PL350520A1 (en) 2002-12-16
CA2363670A1 (en) 2000-08-24
NO990814L (en) 2000-08-21
JP2002537264A (en) 2002-11-05
EP1150690A1 (en) 2001-11-07
SK11602001A3 (en) 2002-02-05
HUP0105280A2 (en) 2002-04-29
HUP0105281A2 (en) 2002-05-29
BR0008302A (en) 2002-08-27
CN1347322A (en) 2002-05-01
AU2834100A (en) 2000-09-04
CA2362306A1 (en) 2000-08-24
AU2834200A (en) 2000-09-04
IL144896A0 (en) 2002-06-30
NO309305B1 (en) 2001-01-15
EP1150689A1 (en) 2001-11-07
CN1347323A (en) 2002-05-01
SK11612001A3 (en) 2002-04-04
JP2002537263A (en) 2002-11-05
IL144895A0 (en) 2002-06-30
PL350519A1 (en) 2002-12-16
MXPA01008347A (en) 2004-03-10
CZ20012965A3 (en) 2002-03-13
NO990814D0 (en) 1999-02-19
WO2000048609A1 (en) 2000-08-24
RU2001123124A (en) 2004-02-20
MXPA01008346A (en) 2003-06-06
CZ20012966A3 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
RU2001123035A (en) CHEMICAL COMPOUNDS
NO20041631L (en) Piperazine derivatives with CCR1 receptor antagonist
WO2002016358A3 (en) Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
GB0119249D0 (en) Organic compounds
PL366726A1 (en) 4'-substituted nucleosides for the treatment of diseases mediated by the hepatitis c virus
CA2413163A1 (en) 3'-prodrugs of 2'-deoxy-.beta.-l-nucleosides
HUP0401434A3 (en) Photosensitizing agent containing sulphonated meso-tetra-phenylporphyrin, process for its preparation and pharmaceutical compositions containing thereof
NO20041994L (en) New beta-phenyl-alpha-oxy-substituted propion derivatives: Process for their preparation and their use in the preparation of pharmaceutically correct compounds
JP2006514012A5 (en)
WO2005007601A3 (en) Substituted arylthiourea derivatives useful as inhibitors of viral replication
RU2003118500A (en) MEANS FOR INHIBITING REPRODUCTION OF COATED VIRUSES, METHOD FOR ITS PRODUCTION, PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING VIRAL INFECTIONS
PT992509E (en) NEW MACROLIDED DERIVATIVES
AU2002341241A1 (en) Process for the preparation of fast dissolving dosage form
GB0109122D0 (en) Novel compounds
GB0029936D0 (en) A pharmaceutical formulation suitable for the treatment of hepititis B, hepititis C and other viral infections of the liver and a process for its preparation
EE200000472A (en) Antineoplastic agents
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
WO2003053971A8 (en) Pyridoquinoxaline antivirals
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
WO2004029064A8 (en) (+)-trans-isomers of (1-phosphonomethoxy-2-alkylcyclopropyl) methyl nucleoside derivatives, process for the preparation of stereoisomers thereof, and use of antiviral agents thereof
HRP20000291B1 (en) High purity (1r, 2s, 4r)-(-)-2-/(2'-/n,n-dimethylamino/-ethoxy)/-2-/phenyl/-1,7,7-tri-/methyl/bicyclo/2.2.1/ heptane and pharmaceutically acceptable acid addition salts thereof and process for the preparation of these compounds as well medicaments containing one or more of them and the use thereof
CA2380852A1 (en) Tricyclic compounds having spiro union
AP9801235A0 (en) Erythromycin derivatives.
SE8402199L (en) PHARMACEUTICAL PREPARATION CONTAINING CO-DERGOCRIN AND A CALCIUM ANTAGONIST
TH49969A (en) Chemical compound